Last edition
News about "pancreatic ductal adenocarcinoma (PDAC) "
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib
Revolution Medicines presented phase 1/2 clinical data showing the potential of zoldonrasib combination regimens in patients with RAS G12D metastatic pancreatic cancer at ESMO Gastrointestinal Cancers Congress 2026.
Pancreatic Ductal Adenocarcinoma (PDAC) | 04/07/2026 | By News Bureau
Bayer and Kumquat Biosciences have begun a Phase-I trial of their KRAS G12D inhibitor targeting KRAS-mutated tumors, further bolstering Bayer’s precision oncology pipeline across pancreatic, colorectal, and lung cancers.
Pancreatic Ductal Adenocarcinoma (PDAC) | 11/10/2025 | By Dineshwori | 909
Cantargia Secures US Patent for Nadunolimab in Cancer Combination Therapies
Cantargia has announced that the United States Patent and Trademark Office (USPTO) has granted a new patent covering its antibody, nadunolimab.
Pancreatic Ductal Adenocarcinoma (PDAC) | 27/08/2025 | By Dineshwori | 314
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy